RCSI mRNA vaccine targeting GPC2 delays neuroblastoma growth 10-11 days in murine models

The study used self-assembling peptide nanoparticles to deliver mRNA encoding GPC2 epitopes in a syngeneic neuroblastoma model. Vaccinated mice mounted CD8+ T-cell responses that slowed tumor establishment and shrank established lesions. This marks the first reported mRNA platform applied to this pediatric solid tumor, which accounts for 15% of childhood cancer deaths and shows 80% treatment resistance at relapse. Neuroblastoma immunotherapy has lagged adult oncology because of low mutational burden and immunosuppressive microenvironments; GPC2 surface expression offers a shared antigen across several pediatric and adult cancers. The LEGO-like modularity noted by lead author Olga Piskareva could allow rapid swapping of epitopes, yet the current data remain limited to one cell line and short-term endpoints. Next steps require validation in patient-derived xenografts, combination with checkpoint blockade, and toxicology studies before IND-enabling work. Parallel GPC2 CAR-T trials already underway in relapsed neuroblastoma will provide comparative benchmarks on safety and durability.